Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis

Cancer and Metastasis Reviews

Volumn 32, Issue 1-2, 2013, Pages 83-107

  Qiu, Wanglong ^a   Su, Gloria H ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Animal models; Carcinogen induced; Genetically engineered; Orthotopic; Pancreatic cancer; Xenograft

Indexed keywords

BRCA2 PROTEIN; CARCINOGEN; K RAS PROTEIN; MYC PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

ALLELE; ALLOGRAFT; ARTICLE; CARCINOGENESIS; CELL LINEAGE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; NONHUMAN; ONCOGENE C MYC; ONCOGENE K RAS; PANCREAS CANCER; PANCREAS METASTASIS; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TRANSGENIC ORGANISM; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; CARCINOGENESIS; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS;

EID: 84878106414     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-012-9408-2     Document Type: Article

References (261)

1. Hruban, R. H., et al. (2001). Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. The American Journal of Surgical Pathology, 25(5), 579-586.
2. Takaori, K., et al. (2006). Current topics on precursors to pancreatic cancer. Advances in Medical Sciences, 51, 23-30.
3. Adsay, N. V. (2003). The "new kid on the block": Intraductal papillary mucinous neoplasms of the pancreas: Current concepts and controversies. Surgery, 133(5), 459-463.
4. Hruban, R. H., Wilentz, R. E., & Kern, S. E. (2000). Genetic progression in the pancreatic ducts. American Journal of Pathology, 156(6), 1821-1825.
5. Wilentz, R. E., Albores-Saavedra, J., & Hruban, R. H. (2000). Mucinous cystic neoplasms of the pancreas. Seminars in Diagnostic Pathology, 17(1), 31-42.
6. Yachida, S., et al. (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 467(7319), 1114-1117.
7. Almoguera, C., et al. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 53(4), 549-554.
8. Caldas, C., et al. (1994). Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genetics, 8, 27-31.
9. Schutte, M., et al. (1997). Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Research, 57, 3126-3130.
10. Redston, M. S., et al. (1994). p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Research, 54, 3025-3033.
11. Pellegata, S., et al. (1994). K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions. Cancer Research, 54, 1556-1560.
12. Hahn, S. A., et al. (1996). DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science, 271(5247), 350-353.
13. Wilentz, R. E., et al. (2000). Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia (PanIN): Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Research, 60, 2002-2006.
14. Su, G. H., & Kern, S. E. (2000). Molecular genetics of ductal pancreatic neoplasia. Curr Opin Gastroenterology, 16, 419-425.
15. Klimstra, D. S., & Longnecker, D. S. (1994). K-ras mutations in pancreatic ductal proliferative lesions. American Journal of Pathology, 145(6), 1547-1550.
16. DiGiuseppe, J. A., et al. (1994). Overexpression of p53 protein in adenocarcinoma of the pancreas. American Journal of Clinical Pathology, 101(6), 684-688.
17. Sato, N., et al. (2001). STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. American Journal of Pathology, 159(6), 2017-2022.
18. Sahin, F., et al. (2003). Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Modern Pathology, 16(7), 686-691.
19. Schonleben, F., et al. (2006). PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clinical Cancer Research, 12(12), 3851-3855.
20. Schonleben, F., et al. (2007). BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Letters, 249(2), 242-248.
21. Corbett, T. H., et al. (1984). Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Research, 44(2), 717-726.
22. Zimmerman, J. A., et al. (1982). Pancreatic carcinoma induced by N-methyl-N′-nitrosourea in aged mice. Gerontology, 28(2), 114-120.
23. Gingell, R., et al. (1976). Metabolism of the pancreatic carcinogens N-nitroso-bis(2-oxopropyl)amine and N-nitroso-bis(2-hydroxypropyl)amine in the Syrian hamster. Journal of the National Cancer Institute, 57(5), 1175-1178.
24. Pour, P., et al. (1976). A further pancreatic carcinogen in Syrian golden hamsters: N-nitroso-bis(2-acetoxypropyl)amine. Cancer Letters, 1(4), 197-202.
25. Pour, P., et al. (1975). Pancreatic neoplasms in an animal model: Morphological, biological, and comparative studies. Cancer, 36(2), 379-389.
26. Roebuck, B. D., Baumgartner, K. J., & Thron, C. D. (1984). Characterization of two populations of pancreatic atypical acinar cell foci induced by azaserine in the rat. Laboratory Investigation, 50(2), 141-146.
27. Roebuck, B. D., & Longnecker, D. S. (1977). Species and rat strain variation in pancreatic nodule induction by azaserine. Journal of the National Cancer Institute, 59(4), 1273-1277.
28. Longnecker, D. S., & Curphey, T. J. (1975). Adenocarcinoma of the pancreas in azaserine-treated rats. Cancer Research, 35(8), 2249-2258.
29. Osvaldt, A. B., et al. (2006). Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice. Surgery, 140(5), 803-809.
30. Bax, J., et al. (1986). Adenosine triphosphatase, a new marker for the differentiation of putative precancerous foci induced in rat pancreas by azaserine. Carcinogenesis, 7(3), 457-462.
31. Roebuck, B. D., Baumgartner, K. J., & Longnecker, D. S. (1987). Growth of pancreatic foci and development of pancreatic cancer with a single dose of azaserine in the rat. Carcinogenesis, 8(12), 1831-1835.
32. Woutersen, R. A., van Garderen-Hoetmer, A., & Longnecker, D. S. (1987). Characterization of a 4-month protocol for the quantitation of BOP-induced lesions in hamster pancreas and its application in studying the effect of dietary fat. Carcinogenesis, 8(6), 833-837.
33. Mizumoto, K., et al. (1989). Cycles of repeated augmentation pressure in rapid production of pancreatic and cholangiocellular carcinomas in hamsters initiated with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis, 10(8), 1457-1459.
34. Meijers, M., et al. (1989). Histogenesis of early preneoplastic lesions induced by N-nitrosobis(2-oxopropyl)amine in exocrine pancreas of hamsters. International Journal of Pancreatology, 4(2), 127-137.
35. Kilian, M., et al. (2006). Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian hamsters: Inhibition of matrix metalloproteinases in pancreatic cancer. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 75(6), 429-434.
36. Kubozoe, T., et al. (2001). Absence of beta-catenin gene mutations in pancreatic duct lesions induced by N-nitrosobis(2-oxopropyl)amine in hamsters. Cancer Letters, 168(1), 1-6.
37. Kokkinakis, D. M., & Scarpelli, D. G. (1989). DNA alkylation in the hamster induced by two pancreatic carcinogens. Cancer Research, 49(12), 3184-3189.
38. Mangino, M. M., Scarpelli, D. G., & Kokkinakis, D. M. (1990). Metabolism and activation of the pancreatic carcinogen N-nitrosobis(2-oxopropyl) amine by isolated hepatocytes and pancreatic cells of the Syrian hamster. Carcinogenesis, 11(4), 625-631.
39. Sugio, K., et al. (1996). High yields of K-ras mutations in intraductal papillary mucinous tumors and invasive adenocarcinomas induced by N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine in the pancreas of female Syrian hamsters. Carcinogenesis, 17(2), 303-309.
40. Longnecker, D. S., et al. (1985). Induction of pancreatic carcinomas in rats with N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine: Histopathology. Journal of the National Cancer Institute, 74(1), 209-217.
41. Bockman, D. E., et al. (1978). Origin of tubular complexes developing during induction of pancreatic adenocarcinoma by 7,12-dimethylbenz(a)anthracene. American Journal of Pathology, 90(3), 645-658.
42. Rivera, J. A., et al. (1997). A rat model of pancreatic ductal adenocarcinoma: Targeting chemical carcinogens. Surgery, 122(1), 82-90.
43. Z'Graggen, K., et al. (2001). Promoting effect of a high-fat/high-protein diet in DMBA-induced ductal pancreatic cancer in rats. Annals of Surgery, 233(5), 688-695.
44. Wendt, L. R., et al. (2007). Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice: Effects of alcohol and caffeine. Acta Cirúrgica Brasileira, 22(3), 202-209.
45. Kimura, K., et al. (2007). Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice. Cancer Science, 98(2), 155-162.
46. Pour, P. M., & Rivenson, A. (1989). Induction of a mixed ductal-squamous-islet cell carcinoma in a rat treated with a tobacco-specific carcinogen. American Journal of Pathology, 134(3), 627-631.
47. Rivenson, A., et al. (1988). Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Research, 48(23), 6912-6917.
48. Schuller, H. M., et al. (1993). Transplacental induction of pancreas tumors in hamsters by ethanol and the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Research, 53(11), 2498-2501.
49. Van Benthem, J., et al. (1994). Immunocytochemical identification of DNA adducts, O6-methylguanine and 7-methylguanine, in respiratory and other tissues of rat, mouse and Syrian hamster exposed to 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone. Carcinogenesis, 15(9), 2023-2029.
50. Hayashi, Y., et al. (1987). Induction of cells with acinar cell phenotype including presence of intracellular amylase. Treatment with 12-O-tetradecanoyl-phorbol-13-acetate in a neoplastic human salivary intercalated duct cell line grown in athymic nude mice. Cancer, 60(5), 1000-1008.
51. Reddy, J. K., & Rao, M. S. (1975). Pancreatic adenocarcinoma in inbred guinea pigs induced by n-methyl-N-nitrosourea. Cancer Research, 35(8), 2269-2277.
52. Rao, M. S., & Reddy, J. K. (1980). Histogenesis of pseudo-ductular changes induced in the pancreas of guinea pigs treated with N-methyl-N- nitrosourea. Carcinogenesis, 1(12), 1027-1037.
53. Chang, K. W., et al. (1994). Genomic p53 mutation in a chemically induced hamster pancreatic ductal adenocarcinoma. Cancer Research, 54(14), 3878-3883.
54. Al-Wadei, H. A., & Schuller, H. M. (2009). Nicotinic receptor-associated modulation of stimulatory and inhibitory neurotransmitters in NNK-induced adenocarcinoma of the lungs and pancreas. The Journal of Pathology, 218(4), 437-445.
55. Longnecker, D. S. (1991). Hormones and pancreatic cancer. International Journal of Pancreatology, 9, 81-86.
56. Lhoste, E. F., & Longnecker, D. S. (1987). Effect of bombesin and caerulein on early stages of carcinogenesis induced by azaserine in the rat pancreas. Cancer Research, 47(12), 3273-3277.
57. McGuinness, E. E., Morgan, R. G., & Wormsley, K. G. (1987). Fate of pancreatic nodules induced by raw soya flour in rats. Gut, 28(Suppl), 207-212.
58. Al-Wadei, H. A., Al-Wadei, M. H., & Schuller, H. M. (2009). Prevention of pancreatic cancer by the beta-blocker propranolol. Anti-Cancer Drugs, 20(6), 477-482.
59. Valentich, M. A., et al. (2006). Effect of the co-administration of phenobarbital, quercetin and mancozeb on nitrosomethylurea-induced pancreatic tumors in rats. Food and Chemical Toxicology, 44(12), 2101-2105.
60. Ouyang, N., et al. (2006). Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Research, 66(8), 4503-4511.
61. Kuroiwa, Y., et al. (2006). Protective effects of benzyl isothiocyanate and sulforaphane but not resveratrol against initiation of pancreatic carcinogenesis in hamsters. Cancer Letters, 241(2), 275-280.
62. Heukamp, I., et al. (2005). Effects of the antioxidative vitamins A, C and E on liver metastasis and intrametastatic lipid peroxidation in BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology, 5(4-5), 403-409.
63. Schuller, H. M., et al. (2002). The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. Journal of Cancer Research and Clinical Oncology, 128(10), 525-532.
64. Strouch, M. J., et al. (2011). A high omega-3 fatty acid diet mitigates murine pancreatic precancer development. Journal of Surgical Research, 165(1), 75-81.
65. Gray, M. J., et al. (2005). Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Research, 65(9), 3664-3670.
66. Bosma, M. J., & Carroll, A. M. (1991). The SCID mouse mutant: Definition, characterization, and potential uses. Annual Review of Immunology, 9, 323-350.
67. Ito, M., et al. (2002). NOD/SCID/gamma(c)(null) mouse: An excellent recipient mouse model for engraftment of human cells. Blood, 100(9), 3175-3182.
68. Quintana, E., et al. (2008). Efficient tumour formation by single human melanoma cells. Nature, 456(7222), 593-598.
69. Hafeez, B.B., et al., Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-kappaB signaling pathways. Int J Cancer, 2012; 131:2175-2186.
70. Girgis, M. D., et al. (2011). Targeting CEA in pancreas cancer xenografts with a mutated scFv-Fc antibody fragment. EJNMMI Research, 1(1), 24.
71. Aurisicchio, L., et al., Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors. J Cell Physiol, 2012;227:3381-3388.
72. Nakamura, M., et al., Targeting the hedgehog signaling pathway with interacting peptides to Patched-1. J Gastroenterol, 2012; 47:452-460.
73. Li, H., et al. (2011). STAT3 knockdown reduces pancreatic cancer cell invasiveness and matrix metalloproteinase-7 expression in nude mice. PLoS One, 6(10), e25941.
74. Fidler, I. J. (1986). Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Reviews, 5(1), 29-49.
75. DeRosier, L. C., et al. (2006). Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo. Journal of Gastrointestinal Surgery, 10(9), 1291-1300. discussion 1300.
76. Capella, G., et al. (1999). Orthotopic models of human pancreatic cancer. Annals of the New York Academy of Sciences, 880, 103-109.
77. Rubio-Viqueira, B., et al. (2006). An in vivo platform for translational drug development in pancreatic cancer. Clinical Cancer Research, 12(15), 4652-4661.
78. Trevino, J. G., et al. (2006). Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. American Journal of Pathology, 168(3), 962-972.
79. Li, C., et al. (2007). Identification of pancreatic cancer stem cells. Cancer Research, 67(3), 1030-1037.
80. Derosier, L. C., et al. (2007). TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Molecular Cancer Therapeutics, 6(12 Pt 1), 3198-3207.
81. Jimeno, A., et al. (2009). A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Molecular Cancer Therapeutics, 8(2), 310-314.
82. Fogh, J., et al. (1980). Thirty-four lines of six human tumor categories established in nude mice. Journal of the National Cancer Institute, 64(4), 745-751.
83. Alisauskus, R., Wong, G. Y., & Gold, D. V. (1995). Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer. Cancer Research, 55(23 Suppl), 5743s-5748s.
84. Killion, J. J., Radinsky, R., & Fidler, I. J. (1998). Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Reviews, 17(3), 279-284.
85. Loukopoulos, P., et al. (2004). Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas, 29(3), 193-203.
86. Huynh, A. S., et al. (2011). Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells. PLoS One, 6(5), e20330.
87. DeRosier, L. C., et al. (2007). Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clinical Cancer Research, 13(18 Pt 2), 5535s-5543s.
88. Partecke, I. L., et al. (2011). In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases model. BMC Cancer, 11, 40.
89. Cheng, L., et al. (1996). Use of green fluorescent protein variants to monitor gene transfer and expression in mammalian cells. Nature Biotechnology, 14(5), 606-609.
90. Chalfie, M., et al. (1994). Green fluorescent protein as a marker for gene expression. Science, 263(5148), 802-805.
91. Astoul, P., et al. (1994). A "patient-like" nude mouse model of parietal pleural human lung adenocarcinoma. Anticancer Research, 14(1A), 85-91.
92. Budinger, T. F., Benaron, D. A., & Koretsky, A. P. (1999). Imaging transgenic animals. Annual Review of Biomedical Engineering, 1, 611-648.
93. Hoffman, R. M. (2005). The multiple uses of fluorescent proteins to visualize cancer in vivo. Nature Reviews. Cancer, 5(10), 796-806.
94. Bouvet, M., et al. (2000). Chronologically-specific metastatic targeting of human pancreatic tumors in orthotopic models. Clinical & Experimental Metastasis, 18(3), 213-218.
95. Bouvet, M., et al. (2002). Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. Cancer Research, 62(5), 1534-1540.
96. Katz, M. H., et al. (2003). A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. Journal of Surgical Research, 113(1), 151-160.
97. Katz, M. H., et al. (2004). An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer. Clinical & Experimental Metastasis, 21(1), 7-12.
98. Bouvet, M., et al. (2005). High correlation of whole-body red fluorescent protein imaging and magnetic resonance imaging on an orthotopic model of pancreatic cancer. Cancer Research, 65(21), 9829-9833.
99. Katz, M. H., et al. (2003). Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer. Cancer Research, 63(17), 5521-5525.
100. Katz, M. H., et al. (2004). Survival efficacy of adjuvant cytosine-analogue CS-682 in a fluorescent orthotopic model of human pancreatic cancer. Cancer Research, 64(5), 1828-1833.
101. Amoh, Y., et al. (2006). Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine. Journal of Surgical Research, 132(2), 164-169.
102. Amoh, Y., et al. (2006). Visualization of nascent tumor angiogenesis in lung and liver metastasis by differential dual-color fluorescence imaging in nestin-linked-GFP mice. Clinical & Experimental Metastasis, 23(7-8), 315-322.
103. Amoh, Y., et al. (2006). Dual-color imaging of nascent angiogenesis and its inhibition in liver metastases of pancreatic cancer. Anticancer Research, 26(5A), 3237-3242.
104. Sweeney, T. J., et al. (1999). Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA, 96(21), 12044-12049.
105. Kunnumakkara, A.B., et al., Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. Int J Cancer 2012; 131:E292-E303.
106. Hingorani, S. R., et al. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 4(6), 437-450.
107. Hingorani, S. R., et al. (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 7(5), 469-483.
108. Tuveson, D. A., & Hingorani, S. R. (2005). Ductal pancreatic cancer in humans and mice. Cold Spring Harbor Symposia on Quantitative Biology, 70, 65-72.
109. Tseng, W.W., et al., Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. Clin Cancer Res. 16(14): p. 3684-95.
110. Partecke, L. I., et al. (2011). A syngeneic orthotopic murine model of pancreatic adenocarcinoma in the C57/BL6 mouse using the Panc02 and 6606PDA cell lines. European Surgical Research, 47(2), 98-107.
111. Wang, B., et al. (2001). A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. International Journal of Gastrointestinal Cancer, 29(1), 37-46.
112. Tseng, W. W., et al. (2010). Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. Clinical Cancer Research, 16(14), 3684-3695.
113. Qiu, W., et al. (2011). Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget, 2(11), 862-873.
114. Chu, Q.D. and R.H. Kim, Immunocompetent orthotopic pancreatic cancer murine model: A step in the right direction. J Surg Res, 2011 [Epub ahead of print]
115. Brembeck, F. H., et al. (2003). The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Research, 63(9), 2005-2009.
116. Jhappan, C., et al. (1990). TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell, 61(6), 1137-1146.
117. Pujal, J., et al. (2009). Keratin 7 promoter selectively targets transgene expression to normal and neoplastic pancreatic ductal cells in vitro and in vivo. The FASEB Journal, 23(5), 1366-1375.
118. Offield, M. F., et al. (1996). PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development, 122(3), 983-995.
119. Aichler, M., et al. (2012). Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: A comparative study in transgenic mice and human tissues. The Journal of Pathology, 226(5), 723-734.
120. Zhu, L., et al. (2007). Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. American Journal of Pathology, 171(1), 263-273.
121. Means, A. L., et al. (2005). Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development, 132(16), 3767-3776.
122. Hruban, R. H., et al. (2006). Pathology of genetically engineered mouse models of pancreatic exocrine cancer: Consensus report and recommendations. Cancer Research, 66(1), 95-106.
123. Ornitz, D. M., et al. (1987). Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. Science, 238(4824), 188-193.
124. Quaife, C. J., et al. (1987). Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice. Cell, 48(6), 1023-1034.
125. Lewis, B. C., Klimstra, D. S., & Varmus, H. E. (2003). The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer. Genes & Development, 17(24), 3127-3138.
126. Sandgren, E. P., et al. (1991). Pancreatic tumor pathogenesis reflects the causative genetic lesion. Proc Natl Acad Sci USA, 88(1), 93-97.
127. Liao, D. J., et al. (2006). Characterization of pancreatic lesions from MT-tgf alpha, Ela-myc and MT-tgf alpha/Ela-myc single and double transgenic mice. J Carcinog, 5, 19.
128. Grippo, P.J. and E.P. Sandgren. Acinar-to-ductal metaplasia accompanies c-myc-induced exocrine pancreatic cancer progression in transgenic rodents. Int J Cancer, 2012;131:1243-1248.
129. Grippo, P. J., et al. (2003). Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. Cancer Research, 63(9), 2016-2019.
130. Jones, S., et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 321(5897), 1801-1806.
131. Thayer, S. P., et al. (2003). Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature, 425(6960), 851-856.
132. Pasca di Magliano, M. (2006). Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes & Development, 20(22), 3161-3173.
133. Sandgren, E. P., et al. (1990). Overexpression of TGF alpha in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell, 61(6), 1121-1135.
134. Schmid, R. M., et al. (1999). Acinar-ductal-carcinoma sequence in transforming growth factor-alpha transgenic mice. Annals of the New York Academy of Sciences, 880, 219-230.
135. Liao, D. J., et al. (2000). Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis. Oncogene, 19(10), 1307-1317.
136. Thorgeirsson, S. S., Factor, V. M., & Snyderwine, E. G. (2000). Transgenic mouse models in carcinogenesis research and testing. Toxicology Letters, 112-113, 553-555.
137. Malka, D., et al. (2002). Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut, 51(6), 849-852.
138. Norman, J. G., et al. (1996). Transgenic animals demonstrate a role for the IL-1 receptor in regulating IL-1beta gene expression at steady-state and during the systemic stress induced by acute pancreatitis. Journal of Surgical Research, 63(1), 231-236.
139. Marrache, F., et al. (2008). Overexpression of interleukin-1beta in the murine pancreas results in chronic pancreatitis. Gastroenterology, 135(4), 1277-1287.
140. Yip-Schneider, M. T., et al. (2000). Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis, 21(2), 139-146.
141. Muller-Decker, K., et al. (2006). Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice. Gastroenterology, 130(7), 2165-2178.
142. Neufang, G., et al. (2001). Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci USA, 98(13), 7629-7634.
143. Colby, J. K., et al. (2008). Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia, 10(8), 782-796.
144. Tang, C., Biemond, I., & Lamers, C. B. (1996). Cholecystokinin receptors in human pancreas and gallbladder muscle: A comparative study. Gastroenterology, 111(6), 1621-1626.
145. Saillan-Barreau, C., et al. (1998). Transgenic CCK-B/gastrin receptor mediates murine exocrine pancreatic secretion. Gastroenterology, 115(4), 988-996.
146. Mathieu, A., et al. (2005). Transgenic expression of CCK2 receptors sensitizes murine pancreatic acinar cells to carcinogen-induced preneoplastic lesions formation. International Journal of Cancer, 115(1), 46-54.
147. Goggins, M., et al. (1998). Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Research, 58, 5329-5332.
148. Kuang, C., et al. (2006). In vivo disruption of TGF-beta signaling by Smad7 leads to premalignant ductal lesions in the pancreas. Proc Natl Acad Sci USA, 103(6), 1858-1863.
149. Izeradjene, K., et al. (2007). Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell, 11(3), 229-243.
150. Wagner, M., et al. (1998). Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice. Gastroenterology, 115(5), 1254-1262.
151. Glasner, S., Memoli, V., & Longnecker, D. S. (1992). Characterization of the ELSV transgenic mouse model of pancreatic carcinoma. Histologic type of large and small tumors. American Journal of Pathology, 140(5), 1237-1245.
152. Bell, R. H., Jr., Memol, V. A., & Longnecker, D. S. (1990). Hyperplasia and tumors of the islets of Langerhans in mice bearing an elastase I-SV40 T-antigen fusion gene. Carcinogenesis, 11(8), 1393-1398.
153. Schaeffer, B. K., Terhune, P. G., & Longnecker, D. S. (1994). Pancreatic carcinomas of acinar and mixed acinar/ductal phenotypes in Ela-1-myc transgenic mice do not contain c-K-ras mutations. American Journal of Pathology, 145(3), 696-701.
154. Efrat, S., et al. (1988). Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene. Proc Natl Acad Sci USA, 85(23), 9037-9041.
155. Bottinger, E. P., et al. (1997). Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas. EMBO Journal, 16(10), 2621-2633.
156. Yamaoka, T., et al. (2000). Diabetes and pancreatic tumours in transgenic mice expressing Pa x 6. Diabetologia, 43(3), 332-339.
157. Wagner, M., et al. (2001). A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes & Development, 15(3), 286-293.
158. Schreiner, B., et al. (2003). Pattern of secondary genomic changes in pancreatic tumors of Tgf alpha/Trp53+/- transgenic mice. Genes, Chromosomes & Cancer, 38(3), 240-248.
159. Bardeesy, N., et al. (2002). Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Molecular and Cellular Biology, 22(2), 635-643.
160. Adrian, K., et al. (2009). Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic precancer. Cancer Research, 69(24), 9169-9174.
161. Grippo, P.J., et al., Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Gut, 2012;61:1454-1464.
162. Krantz, S. B., et al. (2011). MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-beta signaling. Molecular Cancer Research, 9(10), 1294-1304.
163. Sandgren, E. P., et al. (1993). Transforming growth factor alpha dramatically enhances oncogene-induced carcinogenesis in transgenic mouse pancreas and liver. Molecular and Cellular Biology, 13(1), 320-330.
164. Fisher, G. H., et al. (1999). Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene, 18(38), 5253-5260.
165. Morton, J. P., et al. (2008). Trp53 deletion stimulates the formation of metastatic pancreatic tumors. American Journal of Pathology, 172(4), 1081-1087.
166. Song, S. Y., et al. (1999). Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha. Gastroenterology, 117(6), 1416-1426.
167. Greten, F. R., et al. (2001). TGF alpha transgenic mice. A model of pancreatic cancer development. Pancreatology, 1(4), 363-368.
168. Siveke, J. T., et al. (2007). Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell, 12(3), 266-279.
169. Schutte, M., et al. (1996). DPC4 gene in various tumor types. Cancer Research, 56(11), 2527-2530.
170. Bardeesy, N., et al. (2006). Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes & Development, 20(22), 3130-3146.
171. Ijichi, H., et al. (2006). Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes & Development, 20(22), 3147-3160.
172. Kojima, K., et al. (2007). Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia. Cancer Research, 67(17), 8121-8130.
173. Akhurst, R. J. (2002). TGF-beta antagonists: Why suppress a tumor suppressor? The Journal of Clinical Investigation, 109(12), 1533-1536.
174. Mathur, A., et al. (2009). Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. Journal of the American College of Surgery, 208(5), 989-994. discussion 994-6.
175. Yamagishi, S., et al. (2010). Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. Pharmacological Research, 61(2), 103-107.
176. Olive, K. P., et al. (2009). Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science, 324(5933), 1457-1461.
177. Guerra, C., et al. (2007). Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell, 11(3), 291-302.
178. Shields, J. M., et al. (2000). Understanding Ras: 'It ain't over 'til it's over'. Trends in Cell Biology, 10(4), 147-154.
179. Guerra, C., et al. (2003). Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell, 4(2), 111-120.
180. Tuveson, D. A., et al. (2004). Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell, 5(4), 375-387.
181. Pin, C. L., Bonvissuto, A. C., & Konieczny, S. F. (2000). Mist1 expression is a common link among serous exocrine cells exhibiting regulated exocytosis. Anatomical Record, 259(2), 157-167.
182. Pin, C. L., et al. (2001). The bHLH transcription factor Mist1 is required to maintain exocrine pancreas cell organization and acinar cell identity. The Journal of Cell Biology, 155(4), 519-530.
183. Tuveson, D. A., et al. (2006). Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Research, 66(1), 242-247.
184. Shi, G., et al. (2009). Loss of the acinar-restricted transcription factor Mist1 accelerates Kras-induced pancreatic intraepithelial neoplasia. Gastroenterology, 136(4), 1368-1378.
185. Mao, X., Fujiwara, Y., & Orkin, S. H. (1999). Improved reporter strain for monitoring Cre recombinase-mediated DNA excisions in mice. Proc Natl Acad Sci USA, 96(9), 5037-5042.
186. Lakso, M., et al. (1992). Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci USA, 89(14), 6232-6236.
187. Jackson, E. L., et al. (2001). Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes & Development, 15(24), 3243-3248.
188. Carriere, C., et al. (2007). The nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci USA, 104(11), 4437-4442.
189. Leach, S. D. (2005). Epithelial differentiation in pancreatic development and neoplasia: New niches for nestin and Notch. Journal of Clinical Gastroenterology, 39(4 Suppl 2), S78-S82.
190. Fendrich, V., et al. (2008). Hedgehog signaling is required for effective regeneration of exocrine pancreas. Gastroenterology, 135(2), 621-631.
191. Habbe, N., et al. (2008). Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci USA, 105(48), 18913-18918.
192. Trobridge, P., et al. (2009). TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology, 136(5), 1680-1688. e7.
193. Kim, W. Y., et al. (2009). HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. The Journal of Clinical Investigation, 119(8), 2160-2170.
194. Fan, H. Y., et al. (2009). Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. Cancer Research, 69(16), 6463-6472.
195. Dail, M., et al. (2010). Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci USA, 107(11), 5106-5111.
196. Sund, N. J., et al. (2001). Tissue-specific deletion of Foxa2 in pancreatic beta cells results in hyperinsulinemic hypoglycemia. Genes & Development, 15(13), 1706-1715.
197. Su, Y., et al., N-Cadherin haploinsufficiency increases survival in a mouse model of pancreatic cancer. Oncogene, 2012;31;4484-4489.
198. Karlsson, R., et al. (2009). Rho GTPase function in tumorigenesis. Biochimica et Biophysica Acta, 1796(2), 91-98.
199. Heid, I., et al. (2011). Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology, 141(2), 719-730. 730 e1-7.
200. Nakhai, H., et al. (2008). Conditional ablation of Notch signaling in pancreatic development. Development, 135(16), 2757-2765.
201. Stanger, B. Z., et al. (2005). Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell, 8(3), 185-195.
202. Rowley, M., et al. (2011). Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology, 140(4), 1303-1313. e1-3.
203. Feldmann, G., et al. (2011). Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: A mouse model of familial pancreatic cancer. Cancer Biology & Therapy, 11(11), 959-968.
204. Bardeesy, N., et al. (2006). Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA, 103(15), 5947-5952.
205. Corcoran, R. B., et al. (2011). STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Research, 71(14), 5020-5029.
206. Fukuda, A., et al. (2011). Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell, 19(4), 441-455.
207. Siveke, J. T., et al. (2008). Notch signaling is required for exocrine regeneration after acute pancreatitis. Gastroenterology, 134(2), 544-555.
208. Mazur, P. K., et al. (2010). Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA, 107(30), 13438-13443.
209. Morton, J. P., et al. (2010). LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology, 39(2), 586-597. 597 e1-6.
210. Murtaugh, L. C., et al. (2003). Notch signaling controls multiple steps of pancreatic differentiation. Proc Natl Acad Sci USA, 100(25), 14920-14925.
211. Aguirre, A. J., et al. (2003). Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes & Development, 17(24), 3112-3126.
212. Morton, J. P., et al. (2010). Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA, 107(1), 246-251.
213. Vincent, D. F., et al. (2009). Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genetics, 5(7), e1000575.
214. Skoulidis, F., et al. (2010). Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell, 18(5), 499-509.
215. Maniati, E., et al. (2011). Crosstalk between the canonical NF-kappaB and Notch signaling pathways inhibits Ppargamma expression and promotes pancreatic cancer progression in mice. The Journal of Clinical Investigation, 121(12), 4685-4699.
216. Hanlon, L., et al. (2010). Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Research, 70(11), 4280-4286.
217. De La, O. J., et al. (2008). Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci USA, 105(48), 18907-18912.
218. Tinder, T. L., et al. (2008). MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. Journal of Immunology, 181(5), 3116-3125.
219. Mukherjee, P., et al. (2009). Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. Journal of Immunology, 182(1), 216-224.
220. Sharpless, N. E., et al. (2001). Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature, 413(6851), 86-91.
221. Collado, M., et al. (2005). Tumour biology: Senescence in premalignant tumours. Nature, 436(7051), 642.
222. Yan, K. P., et al. (2004). Molecular cloning, genomic structure, and expression analysis of the mouse transcriptional intermediary factor 1 gamma gene. Gene, 334, 3-13.
223. Su, G. H., et al. (2001). ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci USA, 98(6), 3254-3257.
224. Gu, Z., et al. (1998). The type I activin receptor ActRIB is required for egg cylinder organization and gastrulation in the mouse. Genes & Development, 12(6), 844-857.
225. Qiu, W., et al. (2011). Conditional activin receptor type 1B (Acvr1b) knockout mice reveal hair loss abnormality. The Journal of Investigative Dermatology, 131(5), 1067-1076.
226. Schonleben, F., et al. (2008). PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbeck's Archives of Surgery, 393(3), 289-296.
227. Okami, K., et al. (1998). Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Research, 58(3), 509-511.
228. Ying, H., et al. (2011). Pten is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaB-cytokine network. Cancer Discov, 1(2), 158-169.
229. Hill, R., et al. (2010). PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Research, 70(18), 7114-7124.
230. Hruban, R. H., et al. (1999). Familial pancreatic cancer. Annals of Oncology, 4, 69-73.
231. Couch, F. J., et al. (2007). The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiology, Biomarkers & Prevention, 16(2), 342-346.
232. Su, G. H., et al. (1999). Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. American Journal of Pathology, 154, 1835-1840.
233. Giardiello, F. M., et al. (2000). Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology, 119(6), 1447-1453.
234. Ylikorkala, A., et al. (2001). Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science, 293(5533), 1323-1326.
235. Grote, V.A., et al., The Associations of advanced glycation end products and its soluble receptor with pancreatic cancer risk: A case-control study within the prospective EPIC cohort. Cancer Epidemiol Biomarkers Prev, 2012;21:619-628.
236. DiNorcia, J., et al. (2012). RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer. Journal of Gastrointestinal Surgery, 16(1), 104-112. discussion 112.
237. Meylan, E., et al. (2009). Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature, 462(7269), 104-107.
238. Fendrich, V., et al. (2010). The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut, 59(5), 630-637.
239. Ling, J., et al. (2012). KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell, 21(1), 105-120.
240. Gendler, S. J., & Spicer, A. P. (1995). Epithelial mucin genes. Annual Review of Physiology, 57, 607-634.
241. Rowse, G. J., et al. (1998). Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Research, 58(2), 315-321.
242. Whipple, C.A., A.L. Young, and M. Korc, A Kras(G12D)-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. Oncogene, 2012;31:2535-2544.
243. Aikawa, T., et al. (2008). Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. The Journal of Clinical Investigation, 118(1), 89-99.
244. Agbunag, C., & Bar-Sagi, D. (2004). Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Research, 64(16), 5659-5663.
245. Pasca di Magliano, M. (2007). Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One, 2(11), e1155.
246. Morris, J. P., et al. (2010). Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. The Journal of Clinical Investigation, 120(2), 508-520.
247. Heiser, P. W., et al. (2008). Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology, 135(4), 1288-1300.
248. Feldmann, G., et al. (2008). Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut, 57(10), 1420-1430.
249. Plentz, R., et al. (2009). Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology, 136(5), 1741-1749. e6.
250. Funahashi, H., et al. (2007). Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Research, 67(15), 7068-7071.
251. Ijichi, H., et al. (2011). Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. The Journal of Clinical Investigation, 121(10), 4106-4117.
252. Diep, C. H., et al. (2011). Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clinical Cancer Research, 17(9), 2744-2756.
253. Branda, C. S., & Dymecki, S. M. (2004). Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Developmental Cell, 6(1), 7-28.
254. Zheng, B., et al. (2000). Engineering mouse chromosomes with Cre-loxP: Range, efficiency, and somatic applications. Molecular and Cellular Biology, 20(2), 648-655.
255. Brayton, C. F., Treuting, P. M., & Ward, J. M. (2012). Pathobiology of aging mice and GEM: Background strains and experimental design. Veterinary Pathology, 49(1), 85-105.
256. Jorgenson, T. C., et al. (2010). Identification of susceptibility loci in a mouse model of KRASG12D-driven pancreatic cancer. Cancer Research, 70(21), 8398-8406.
257. Yu, R., et al. (2011). Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice. PLoS One, 6(8), e23397.
258. Rhim, A. D., et al. (2012). EMT and dissemination precede pancreatic tumor formation. Cell, 148(1-2), 349-361.
259. Collins, M. A., et al. (2012). Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. The Journal of Clinical Investigation, 122(2), 639-653.
260. Wang, Y., et al. (2011). Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. The Journal of Clinical Investigation, 121(3), 893-904.
261. Ventura, A., et al. (2007). Restoration of p53 function leads to tumour regression in vivo. Nature, 445(7128), 661-665.